Filing Flows

Filing Flows › Citius Pharmaceuticals (CTXR) › Who owns the stock

Who owns Citius Pharmaceuticals (CTXR) stock

38 funds reported Citius Pharmaceuticals (CTXR) shares in their latest 13F filings, worth $978K in all. The largest holder is Vanguard Group ($155K). Last quarter 17 funds added to their stakes and 13 cut them.

Largest holders of CTXR (13F)Largest holders of CTXR (13F)Vanguard Group$155KGeode Capital Management, LLC$130KVanguard Capital Management LLC$119KMiller Financial Services LLC$82KCitadel Advisors LLC$76KJane Street Group, LLC$74KVanguard Fiduciary Trust$47KBlackRock$42KNorthern Trust$38KXTX Topco$36K

Largest holders (13F)

FundSharesValueChangeQuarter
Vanguard Group199,258$155Kincrease2025-12-31
Geode Capital Management, LLC215,537$130Kdecrease2026-06-30
Vanguard Capital Management LLC197,364$119Kincrease2026-06-30
Miller Financial Services LLC154,000$82Kincrease2026-09-30
Citadel Advisors LLC124,910$76Knew2026-06-30
Jane Street Group, LLC122,837$74Kincrease2026-06-30
Vanguard Fiduciary Trust77,755$47Kunchanged2026-06-30
BlackRock69,850$42Kdecrease2026-06-30
Northern Trust62,742$38Kincrease2026-06-30
XTX Topco59,199$36Kincrease2026-06-30
Asset Advisory Group59,011$31Kunchanged2026-09-30
StoneX Group36,414$20Knew2026-09-30
UBS Group AG26,335$16Kdecrease2026-06-30
LPL Financial LLC25,445$15Kincrease2026-06-30
State Street23,271$14Kunchanged2026-06-30

Citius Pharmaceuticals' latest quarter

Citius Pharmaceuticals, Q3 FY26: revenue $1.5M, operating margin -785.4%, net loss $11.9M, operating cash flow −$8.7M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most CTXR stock?

By the latest 13F filings: Vanguard Group ($155K); Geode Capital Management, LLC ($130K); Vanguard Capital Management LLC ($119K); Miller Financial Services LLC ($82K); Citadel Advisors LLC ($76K).

What is the short interest in CTXR?

5,698,085 shares were sold short at the 2026-10-15 settlement, 1.95% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.